Phase II study of low-dose interleukin-11 in patients with myelodysplastic syndrome

Leukemia and Lymphoma

Volumn 47, Issue 10, 2006, Pages 2049-2054

  Montero, Alberto J ^a   Estrov, Zeev ^b   Freireich, Emil J ^b   Khouri, Issa F ^b   Koller, Charles A ^b   Kurzrock, Razelle ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

IL 11; MDS; Neumega; Oprelvekin; Thrombocytopenia

Indexed keywords

ARSENIC TRIOXIDE; CYCLOSPORIN; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; IMMUNOGLOBULIN; INTERLEUKIN 11; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; THALIDOMIDE; THYMOCYTE ANTIBODY; TIPIFARNIB;

ACCURACY; ADULT; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; ANEMIA; ARTICLE; BLEEDING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; HEART ATRIUM FIBRILLATION; HEMATOMA; HUMAN; LACRIMAL GLAND DISEASE; LOW DRUG DOSE; MALE; MEDICAL DECISION MAKING; MYELODYSPLASTIC SYNDROME; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; RISK ASSESSMENT; THORAX PAIN; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BLOOD PLATELETS; FEMALE; HUMANS; INTERLEUKIN-11; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PLATELET COUNT; RECOMBINANT PROTEINS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 33750453783     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190600758058     Document Type: Article

References (33)

1. Heaney, M and Golde, D. (1999) Myelodysplasia N Engl J Med, 340, pp. 1649-1660.
2. Silverman, L. (2003) The myelodysplastic syndrome. In. Hamilton BC: Decker.
3. Norfolk, D and Ancliffe, P and Contreras, M and Hunt, B and Machin, S and Murphy, W and (1998) Consensus Conference on Platelet Transfusion, Royal College of Physicians of Edinburgh, 27 - 28 November 1997. Synopsis of background papers Br J Haematol, 101, pp. 609-617.
4. Silberman, S. (1999) Platelets: Preparations, transfusion, modifications, and substitutes Arch Pathol Lab Med, 123, pp. 889-894.
5. Kurzrock, R. (2005) Thrombopoietic factors in chronic bone marrow failure states: The platelet problem revisited Clin Cancer Res, 11, pp. 1361-1367.
6. Saba, H. (1996) Myelodysplastic syndromes in the elderly: The role of growth factors in management Leuk Res, 20, pp. 203-219.
7. Kaye, J. (1998) FDA licensure of NEUMEGA to prevent severe chemotherapy-induced thrombocytopenia Stem Cells, 16(Suppl 2), pp. 207-223.
8. Isaacs, C and Robert, N and Bailey, F and Schuster, M and Overmoyer, B and Graham, M and (1997) Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin J Clin Oncol, 15, pp. 3368-3377.
9. Tepler, I and Elias, L and Smith, J, 2nd and Hussein, M and Rosen, G and Chang, A and (1996) A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy Blood, 87, pp. 3607-3614.
10. Kurzrock, R and Cortes, J and Thomas, D and Jeha, S and Pilat, S and Talpaz, M. (2001) Pilot study of low-dose interleukin-11 in patients with bone marrow failure J Clin Oncol, 19, pp. 4165-4172.
11. Tsimberidou, A and Giles, F and Khouri, I and Bueso-Ramos, C and Pilat, S and Thomas, D and (2005) Low-dose interleukin-11 in patients with bone marrow failure: Update of the M. D. Anderson Cancer Center experience Ann Oncol, 16, pp. 139-145.
12. Cheson, B and Bennett, J and Kantarjian, H and Pinto, A and Schiffer, C and Nimer, S and (2000) Report of an international working group to standardize response criteria for myelodysplastic syndromes Blood, 96, pp. 3671-364.
13. Bernasconi, C and Alessandrino, E and Bernasconi, P and Bonfichi, M and Lazzarino, M and Canevari, A and (1998) Randomized clinical study comparing aggressive chemotherapy with or without G-CSF support for high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia evolving from MDS Br J Haematol, 102, pp. 678-683.
14. Chuncharunee, S and Intragumtornchai, T and Chaimongkol, B and Prayoonwiwat, W and Leelasiri, A and Lekhakula, A and (2001) Treatment of myelodysplastic syndrome with low-dose human granulocyte colony-stimulating factor: A multicenter study Int J Hematol, 74, pp. 144-146.
15. Hellstrom-Lindberg, E and Ahlgren, T and Beguin, Y and Carlsson, M and Carneskog, J and Dahl, I and (1998) Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: Results from a randomized phase II study and long-term follow-up of 71 patients Blood, 92, pp. 68-75.
16. Negrin, R and Haeuber, D and Nagler, A and Kobayashi, Y and Sklar, J and Donlon, T and (1990) Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor Blood, 76, pp. 36-43.
17. Remacha, A and Arrizabalaga, B and Villegas, A and Manteiga, R and Calvo, T and Julia, A and (1999) Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes Identification of a subgroup of responders. The Spanish Erythropathology Group. Haematologica, 84, pp. 1058-1064.
18. Economopoulos, T and Mellou, S and Papageorgiou, E and Pappa, V and Kokkinou, V and Stathopoulou, E and (1999) Treatment of anemia in low risk myelodysplastic syndromes with granulocyte-macrophage colony-stimulating factor plus recombinant human erythropoietin Leukemia, 13, pp. 1009-1012.
19. Thompson, J and Gilliland, D and Prchal, J and Bennett, J and Larholt, K and Nelson, R and (2000) Effect of recombinant human erythropoietin combined with granulocyte/macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome. GM/EPO MDS Study Group Blood, 95, pp. 1175-1179.
20. Vadhan-Raj, S and Keating, M and LeMaistre, A and Hittelman, W and McCredie, K and Trujillo, J and (1987) Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes N Engl J Med, 317, pp. 1545-1552.
21. Kurzrock, R and Talpaz, M and Estey, E and O'Brien, S and Estrov, Z and Gutterman, J. (1991) Erythropoietin treatment in patients with myelodysplastic syndrome and anemia Leukemia, 5, pp. 985-990.
22. Verhoef, G and Zachee, P and Ferrant, A and Demuynck, H and Selleslag, D and van Hove, L and (1992) Recombinant human erythropoietin for the treatment of anemia in the myelodysplastic syndromes: A clinical and erythrokinetic assessment Ann Hematol, 64, pp. 16-21.
23. Du, X and Neben, T and Goldman, S and Williams, D. (1993) Effects of recombinant human interleukin-11 on hematopoietic reconstitution in transplant mice: Acceleration of recovery of peripheral blood neutrophils and platelets Blood, 81, pp. 27-34.
24. Kuter, D. (2000) Future directions with platelet growth factors Semin Hematol, 37(2 Suppl 4), pp. 41-49.
25. Nash, R and Kurzrock, R and DiPersio, J and Vose, J and Linker, C and Maharaj, D and (2000) A phase I trial of recombinant human thrombopoietin in patients with delayed platelet recovery after hematopoietic stem cell transplantation Biol Blood Marrow Transplant, 6, pp. 25-34.
26. Adams, J and Liu Yin, J and Brereton, M and Briggs, M and Burgess, R and Hyde, K. (1997) The in vitro effect of pegylated recombinant human megakaryocyte growth and development factor (PEG rHuMGDF) on megakaryopoiesis in normal subjects and patients with myelodysplasia and acute myeloid leukaemia Br J Haematol, 99, pp. 139-146.
27. Fanucchi, M and Glaspy, J and Crawford, J and Garst, J and Figlin, R and Sheridan, W and (1997) Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer N Engl J Med, 336, pp. 404-409.
28. Fontenay-Roupie, M and Dupont, J and Picard, F and Fichelson, S and Botella, A and Melle, J and (1998) Analysis of megakaryocyte growth and development factor (thrombopoietin) effects on blast cell and megakaryocyte growth in myelodysplasia Leuk Res, 22, pp. 527-535.
29. Schuster, M and Beveridge, R and Frei-Lahr, D and Abboud, C and Cruickshank, S and Macri, M and (2002) The effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on platelet recovery in breast cancer patients undergoing autologous bone marrow transplantation Exp Hematol, 30, pp. 1044-1050.
30. Kurzrock, R and Talpaz, M and Estrov, Z and Rosenblum, M and Gutterman, J. (1991) Phase I study of recombinant human interleukin-3 in patients with bone marrow failure J Clin Oncol, 9, pp. 1241-1250.
31. Wu, H and Talpaz, M and Champlin, R and Pilat, S and Kurzrock, R. (2003) Sequential interleukin 3 and granulocyte-macrophage-colony stimulating factor therapy in patients with bone marrow failure with long-term follow-up of responses Cancer, 98, pp. 2410-2419.
32. Kurzrock, R. (1998) Trilineage responses seen with stem cell factor and filgrastim treatment in aplastic anemia patients Br J Haematol, 102(1). abstract PL-0004
33. Gordon, M and Nemunaitis, J and Hoffman, R and Paquette, R and Rosenfeld, C and Manfreda, S and (1995) A phase I trial of recombinant human interleukin-6 in patients with myelodysplastic syndromes and thrombocytopenia Blood, 85, pp. 3066-3076.